JNJ•benzinga•
Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
Summary
Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients with no new safety concerns.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 4, 2025 by benzinga